Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Pfizer Inc. logo

NYSE · PFE

Pfizer Inc.

Healthcare · Drug Manufacturers - General

$30.52

Up+$0.57 (+1.90%)

Updated Oct 31, 2026, 2:47 PM

SID Score

7.5/10

Composite research score

Smart Money

55/100

Neutral

Market cap
146.75B
P/E ratio
14.94
Dividend yield
5.64%
52-week range
$23.62 – $30.67
Volume
45.49M
Avg. volume
68.83M

Price performance · PFE

PFE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PFE closed at $30.52 after 21 trading sessions, up 9.78% for the selected period.

Last close
$30.52
Period change
+9.78%
Period low
$27.41
Period high
$30.52
Daily close
View OHLC price history
PFE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$30.51$30.67$30.14$30.5245.49M
Oct 29, 2026$29.99$30.18$29.61$29.9534.26M
Oct 28, 2026$29.49$29.815$29.22$29.4527.26M
Oct 27, 2026$29.54$29.86$29.51$29.8025.59M
Oct 26, 2026$30.00$30.305$29.715$29.7925.66M
Oct 23, 2026$30.28$30.32$29.81$30.0329.48M
Oct 22, 2026$30.045$30.44$29.88$30.4228.7M
Oct 21, 2026$30.00$30.09$29.69$29.8522.22M
Oct 20, 2026$29.67$30.25$29.59$30.1134.44M
Oct 19, 2026$29.305$29.69$29.25$29.4420.82M
Oct 16, 2026$29.72$29.74$29.42$29.5828.63M
Oct 15, 2026$29.57$29.88$29.42$29.4432.89M
Oct 14, 2026$28.60$29.49$28.55$29.2139.37M
Oct 13, 2026$28.61$28.61$28.13$28.3726.84M
Oct 12, 2026$28.42$28.495$28.28$28.4018.56M
Oct 9, 2026$27.61$28.285$27.59$28.2823.2M
Oct 8, 2026$27.90$28.00$27.475$27.8244.43M
Oct 7, 2026$27.62$28.17$27.55$28.0031.23M
Oct 6, 2026$27.48$27.71$27.20$27.5024.07M
Oct 5, 2026$27.65$27.72$27.12$27.4133.01M
Oct 2, 2026$28.145$28.16$27.44$27.8035.01M

Latest PFE news

The latest Smart Investors Daily articles mentioning PFE.

Stock researchCompany · Overview

PFE research

Overview

Company profile and research snapshot.

Company profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$30.00
Implied upside
—
Analysts
14
PFE recent ratings
DateFirmRatingTarget
Oct 9, 2026JP MorganNeutral—
Oct 8, 2026Cantor FitzgeraldNeutral—
Oct 6, 2026ScotiabankSector Outperform—
Sep 10, 2026HSBCHold—
Aug 7, 2026GuggenheimBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Pfizer's 25-Valent Pediatric Pneumococcal Conjugate Vaccine Candidate Shows Robust Phase 2 Data at IDWeek 2026

NEW YORK, October 24, 2026--Pfizer Inc. (NYSE: PFE) today announced detailed results across serotypes from a Phase 2 study (NCT06524414) for its investigational 25-valent pneumococcal conjugate vaccine candidate, PF-07872412 (25vPnC), in infants. In the study, a four-dose series of 25vPnC elicited robust immune responses against all 25 serotypes and showed safety and tolerability comparable to four doses of PREVNAR 20® (Pneumococcal 20-valent Conjugate Vaccine). These findings were shared today

Yahoo · Oct 24, 2026

Is Pfizer (PFE) Cheap As Its Enodia Deal Fuels Oncology Growth Hopes?

Pfizer (PFE) is back in focus after signing a research collaboration and license agreement with Enodia Therapeutics that gives the drugmaker access to Enodia’s Sec61 inhibitor programs for potential oncology and specialty treatments. Pfizer’s agreement with Enodia lands at a time when momentum in the shares has been rebuilding, with a 30 day share price return of 6.56% and a 90 day gain of 22.37%. The 1 year total shareholder return of 29.79% contrasts with a weaker 5 year total shareholder...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By